Novel predictive biomarkers of response to immune checkpoint blockade with nivolumab ± ipilimumab in the TITAN-RCC phase 2 trial.

被引：0
|
作者：
Grimm, Marc-Oliver
Kesselmeier, Miriam
Leucht, Katharina
Schumacher, Ulrike
Tunger, Antje
Rober, Nadja
Conrad, Karsten
Sommer, Ulrich
Baretton, Gustavo Bruno
Scherag, Andre
Albiges, Laurence
Esteban, Emilio
Barthelemy, Philippe
Schmidinger, Manuela
Busch, Jonas
Perez-Valderrama, Begona
de Velasco, Guillermo
Duran, Ignacio
Schmitz, Marc
Wehner, Rebekka
机构：
[1] Jena Univ Hosp, Dept Urol, Jena, Germany
[2] Jena Univ Hosp, Inst Med Stat Comp & Data Sci, Jena, Germany
[3] Jena Univ Hosp, Ctr Clin Studies, Jena, Germany
[4] Tech Univ Dresden, Fac Med Carl Gustav Carus, Inst Immunol, Dresden, Germany
[5] Univ Hosp Carl Gustav Carus, Inst Pathol, Dresden, Germany
[6] Univ Paris Sud, Gustave Roussy Canc Campus, Dept Canc Med, Villejuif, France
[7] Hosp Univ Cent Asturias, Dept Med Oncol, Oviedo, Spain
[8] Inst Cancerol Strasbourg Europe, Dept Med Oncol, Strasbourg, France
[9] Med Univ Wien, Vienna Gen Hosp AKH, Dept Internal Med 1, Vienna, Austria
[10] Univ Hosp Charite Berlin, Dept Urol, Berlin, Germany
[11] Hosp Univ Virgen Rocio, Dept Med Oncol, Seville, Spain
[12] Hosp 12 Octubre, Dept Oncol, Madrid, Spain
[13] Hosp Univ Marques Valdecilla, Dept Med Oncol, Santander, Spain
[14] Tech Univ Dresden, Fac Med Carl Gustav Carus, Dept Immunol, Dresden, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 06期
关键词：
D O I：
10.1200/JCO.2022.40.6_suppl.367
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
367
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Dual immune checkpoint inhibition in metastatic renal cell carcinoma Editorial re.: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced RCC: extended 4-year follow-up of the phase III CheckMate 214 trial
    Schmidinger, M.
    Shariat, S. F.
    Fajkovic, H.
    ESMO OPEN, 2021, 6 (01)
  • [22] Nivolumab plus ipilimumab for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC): Additional results from the randomized phase 2 CheckMate 650 trial.
    Sharma, Padmanee
    Krainer, Michael
    Saad, Fred
    Castellano, Daniel
    Bedke, Jens
    Kwiatkowski, Mariusz
    Patnaik, Akash
    Procopio, Giuseppe
    Wiechno, Pawel
    Kochuparambil, Samith Thomas
    Thomas, Christian
    Arija, Jose Angel Arranz
    McCune, Steven L.
    Hansen, Steinbjorn
    Daugaard, Gedske
    Amin, Neha P.
    Wang, Yumeng
    David, Justin M.
    Pachynski, Russell Kent
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [23] Tailored immunotherapy approach with nivolumab with or without ipilimumab in patients with advancedtransitional cell carcinoma after platinum-based chemotherapy (TITAN-TCC): a multicentre, single-arm, phase 2 trial
    Grimm, Marc-Oliver
    Gruen, Christine Barbara
    Niegisch, Guenter
    Pichler, Martin
    Roghmann, Florian
    Schmitz-Draeger, Bernd
    Baretton, Gustavo
    Schmitz, Marc
    Bolenz, Christian
    Foller, Susan
    Leucht, Katharina
    Schumacher, Ulrike
    Schostak, Martin
    Meran, Johannes
    Loidl, Wolfgang
    Zengerling, Friedemann
    LANCET ONCOLOGY, 2023, 24 (04): : 347 - 359
  • [24] Exploratory analysis of biomarkers of response to durvalumab in advanced HER2-negative oesophago-gastric adenocarcinoma within a phase 2 clinical trial.
    Lote, Hazel
    Giota, Eleftheria
    Fong, Caroline
    Gordon, Anderley
    Begum, Ruwaida
    Satchwell, Laura
    Kidd, Shannon
    Cromarty, Susan
    Fribbens, Charlotte Victoria
    Starling, Naureen
    Rao, Sheela
    Chau, Ian
    Cunningham, David
    Zapata, Luis
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 384 - 384
  • [25] A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
    Sun, Kai
    Xu, Yitian
    Zhang, Licheng
    Niravath, Polly
    Darcourt, Jorge
    Patel, Tejal
    Teh, Bin S.
    Farach, Andrew M.
    Guerrero, Carlo
    Mathur, Sunil
    Sultenfuss, Mark A.
    Gupta, Nakul
    Schwartz, Mary R.
    Haley, Susan L.
    Nair, Sindhu
    Li, Xiaoxian
    Nguyen, Thi Truc Anh
    Butner, Joseph D.
    Ensor, Joe
    Mejia, Jaime A.
    Mei, Zhuyong
    Butler, E. Brian
    Chen, Shu-Hsia
    Bernicker, Eric H.
    Chang, Jenny C.
    CLINICAL CANCER RESEARCH, 2022, 28 (20) : 4392 - 4401
  • [26] Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
    Nguyen, Charles B.
    Reimers, Melissa A.
    Perera, Chamila
    Abida, Wassim
    Chou, Jonathan
    Feng, Felix Y.
    Antonarakis, Emmanuel S.
    Mckay, Rana R.
    Pachynski, Russell K.
    Zhang, Jingsong
    Reichert, Zachery R.
    Palmbos, Phillip L.
    Caram, Megan E. V.
    Vaishampayan, Ulka N.
    Heath, Elisabeth I.
    Hopkins, Alexander C.
    Cieslik, Marcin P.
    Wu, Yi-Mi
    Robinson, Dan R.
    Baladandayuthapani, Veerabhadran
    Chinnaiyan, Arul M.
    Alva, Ajjai S.
    CLINICAL CANCER RESEARCH, 2024, 30 (15) : 3200 - 3210
  • [27] Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE)
    Swami, Nishwant
    Hwang, William L.
    Guo, Jimmy A.
    Hoffman, Hannah
    Abramowitz, Matthew C.
    Elbakouny, Ziad
    Beltran, Himisha
    Chipidza, Fallon
    Choueiri, Toni
    Dal Pra, Alan
    Huang, Franklin
    Kaochar, Salma
    Kantoff, Philip
    Kim, Daniel W.
    Kishan, Amar U.
    Kobetz, Erin
    Marinac, Catherine
    Mucci, Lorelei A.
    Muralidhar, Vinayak
    Pollack, Alan
    Sanford, Nina N.
    Schaeffer, Edward M.
    Spratt, Daniel E.
    Zhao, Shuang G.
    Rebbeck, Timothy R.
    Nguyen, Paul L.
    Feng, Felix Y.
    Mahal, Brandon A.
    Alshalalfa, Mohammed
    CANCER GENETICS, 2021, 258 : 61 - 68
  • [28] Safety, Efficacy, and Biomarkers of Response to Azacitidine (AZA) with Nivolumab (Nivo) and AZA with Nivo and Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Phase 2 Study
    Daver, Naval G.
    Garcia-Manero, Guillermo
    Basu, Sreyashi
    Cortes, Jorge E.
    Ravandi, Farhad
    Kadia, Tapan M.
    Konopleva, Marina Y.
    Jabbour, Elias J.
    DiNardo, Courtney D.
    Assi, Rita
    Pierce, Sherry A.
    Alvarado, Yesid
    Estrov, Zeev E.
    Pemmaraju, Naveen
    Takahashi, Koichi
    Ning, Jing
    Gonzalez, Graciela M. Nogueras
    Kornblau, Steven M.
    Alfayez, Mansour
    Matthews, Jairo
    Flores, Wilmer
    Blando, Jorge
    Allison, James P.
    Sharma, Padmanee
    Kantarjian, Hagop M.
    BLOOD, 2018, 132
  • [29] Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer
    Campbell, Michael J.
    Wolf, Denise M.
    Yau, Christina
    Brown-Swigart, Lamorna
    Wulfkuhle, Julie
    Gallagher, Isela R.
    Zhu, Zelos
    Bolen, Jennifer
    Vandenberg, Scott
    Hoyt, Clifford
    Mori, Hidetoshi
    Borowsky, Alexander
    Sit, Laura
    Perlmutter, Jane
    Asare, Smita M.
    Nanda, Rita
    Liu, Minetta C.
    Yee, Douglas
    Demichele, Angela M.
    Hylton, Nola M.
    Pusztai, Lajos
    Berry, Donald A.
    Hirst, Gillian L.
    Petricoin, Emanuel F.
    van't Veer, Laura
    Esserman, Laura
    CELL REPORTS MEDICINE, 2024, 5 (11)
  • [30] Predictive biomarkers for the efficacy of nivolumab as ≥ 3rd-line therapy in patients with advanced gastric cancer: a subset analysis of ATTRACTION-2 phase III trial
    Jwa Hoon Kim
    Min-Hee Ryu
    Young Soo Park
    Jungeun Ma
    Sun Young Lee
    Deokhoon Kim
    Yoon-Koo Kang
    BMC Cancer, 22
12345